The prevention and treatment of infection is central to the optimal management of transplant recipients. Successful avoidance and management of infections in the immunocompromised renal transplant recipient are complicated by a variety of factors.[@bb0010] These include increased susceptibility to a broad spectrum of infectious pathogens, difficulty in making a diagnosis of infection in the face of diminished signs and symptoms of infection, an array of noninfectious etiologies of fever (e.g., graft rejection, drug toxicity), and the possibility that multiple processes are present simultaneously. Further, because immunocompromised patients tolerate invasive and established infection poorly with high morbidity and mortality, the urgency for an early and specific diagnosis to guide antimicrobial therapy is increased. Given the primacy of T lymphocyte dysfunction in transplantation, viral infections in particular are increased and contribute to systemic illness, graft dysfunction and rejection, and enhance the risk for other opportunistic infections (e.g., *Pneumocystis* and *Aspergillus* species) and for virally-mediated cancers.

Risk of infection {#s0010}
=================

The risk of infection in the renal transplant recipient is determined by the interface of two factors:1.The epidemiological exposures of the organ recipient and the donor, including those unrecognized by the patient or distant in time ([Table 38-1](#t0010){ref-type="table"} ); exposures of importance include environmental, community, and nosocomial-acquired exposures.TABLE 38-1Significant Epidemiological Exposures Relevant to Transplantation**DONOR-DERIVEDViral**Herpes family (cytomegalovirus, Epstein-Barr virus, human herpes viruses 6, 7, 8, herpes simplex)Hepatitis viruses (notably B and C, newly emerging E)Retroviruses (HIV, HTLV-1 and -2)Others (LCMV, rabies)**Bacteria**Gram-positive and gram-negative bacteria (*Staphylococcus* species, *Pseudomonas* spp., Enterobacteriaceae)Mycobacteria (tuberculosis and nontuberculous)*Nocardia asteroides***Fungi***Candida* species*Aspergillus* speciesEndemic fungi (*Cryptococcus neoformans*)Geographic fungi (*Histoplasma capsulatum, Coccidioides immitis, Blastomyces*)**Parasites***Toxoplasma gondiiTrypanosoma cruzi***NOSOCOMIO EXPOSURE**MRSAVRE; linezolid and quinupristin-dalfopristin resistance also reported*Aspergillus* species*Candida* nonalbicans strains**COMMUNITY EXPOSURE**Food and water-borne (*Li*s*teria monocytogenes*, *Salmonella* spp., *Cryptosporidium*, hepatitis A, *Campylobacter* spp.)Respiratory viruses (RSV, influenza, parainfluenza, adenovirus, metapneumovirus)Common viruses: often with exposure to children (Coxsackie, parvovirus B19, rotavirus, polyomavirus, papilloma virus)Atypical respiratory pathogens (*Legionella* spp., *Mycoplasma* spp., *Chlamydia*)Geographic fungi, *Cryptococcus*, *Pneumocystis jiroveci*Parasites (often distant)*Strongyloides stercoralisToxoplasma gondiiLeishmania* species*Trypanosoma cruzi* (Chagas disease)*Naegleria* spp. (Acanthamoeba)[^1]2.The patient\'s net state of immunosuppression, including all of the factors contributing to the risk for infection in the transplant recipient ([Table 38-2](#t0015){ref-type="table"} )TABLE 38-2Factors Contributing to the Net State of ImmunosuppressionImmunosuppressive therapy: type, intensity, durationPrior therapies (chemotherapy or antimicrobials)Mucocutaneous barrier integrity (catheters, lines, drains)Neutropenia, lymphopenia (often drug-induced)Underlying immune deficiencyHypogammaglobulinemia from immunosuppression, proteinuria or malnutritionSystemic lupus, complement deficienciesMetabolic conditions: uremia, malnutrition, diabetes, alcoholism/cirrhosisViral infection (CMV, hepatitis B and C, HIV, RSV, EBV)Graft rejectionCancer/cellular proliferation[^2]

Epidemiological Exposures {#s0015}
-------------------------

Further evaluation of the epidemiology of the patient allows the clinician to establish a differential diagnosis for a given "infectious" presentation and to design the optimal preventive strategy for each patient. Donor and recipient screening prior to transplantation are critical components to the post-transplantation health maintenance of the patient ([Table 38-3](#t0020){ref-type="table"} ). Empiric therapy or prophylaxis should be strongly considered in transplant recipients with latent infection with tuberculosis (TB), *Strongyloides stercoralis*, coccidiomycosis, and for patients known to have received organs from donors with acute bacterial and fungal infections. Specific antiviral strategies stratified according to individual risk should be considered for all kidney recipients.TABLE 38-3The Pretransplantation Evaluation of the Donor and Recipient (Consider the Following)Laboratory TestAll PatientsPatients with Exposure to Endemic AreaQuantitative Viral Studies Available (PCR)SerologiesCMV√√HSV√√VZV√EBV√√HIV√√HBV: HbsAg√√anti-HBs√HCV√√*Treponema pallidum*√*Toxoplasma gondii*√*Strongyloides stercoralis*√Stool ova and parasite*Leishmania* spp.√Biopsy of affected region*Trypanosoma cruzi*√Blood smear*Histoplasma capsulatum*√Body fluid antigen assay*Cryptococcus neoformans*√Cryptococcal antigen*Coccidioides immitis*√Body fluid antigen assayCultures, etc.Urinalysis and culture√Skin test: PPD or QuantiFERON Gold√Chest x-ray (routine)√Stool ova and parasites√Urine ova and parasites/cystoscopy√ (for kidneys, in *Schistosoma* endemic areas)[^3]

Donor-Derived Infections {#s0020}
------------------------

Infections transmitted from the donor tissue(s) to the recipient are among the most important exposures in transplantation, as the recipient is likely to be nonimmune and significantly immunosuppressed. Some of these infections are latent, while others are the result of bad timing, with active infection transmitted at the time of transplantation. Numerous such infections have been recognized in transplant recipients, ranging from common and expected pathogens to unexpected pathogens such as lymphocytic choriomeningitis virus,[@bb0010] Chagas disease,[@bb0015] rabies,[@bb0020] and TB. Three types of infection merit special attention. First, in donors who are bacteremic or have fungemia at the time of donation, such infections (staphylococci, pneumococcus, *Candida* species, *Salmonella, Escherichia coli*) may tend to "stick" to anastomotic sites (vascular, urinary) and may produce leaks, mycotic aneurysms, or surgical site infections. Second, viral infections, including cytomegalovirus (CMV) and Epstein-Barr virus (EBV), are associated with particular syndromes and morbidity in the immunocompromised population (discussed later in text); the greatest risk of such infections is in recipients who are seronegative (immunologically naïve) and receive infected grafts from seropositive donors (with latent or active viral infection). Third, latent infections, including TB, may activate many years after the initial exposure. Disseminated mycobacterial infection is often difficult to treat once established largely because of the significant immunosuppression and interactions between the antimicrobial agents used to treat infection (e.g., rifampin, streptomycin, isoniazid) and the agents used in immune suppressive therapy.

Given the risk of transmission of infection from the organ donor to the recipient, certain infections should be considered relative contraindications to organ donation. Given that renal transplantation is, in general, elective surgery, it is reasonable to avoid donation from individuals with unexplained fever, rash, or infectious syndromes. Some of the common criteria for exclusion of organ donors are listed in [Table 38-4](#t0025){ref-type="table"} ; the U.S. Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) Definition of Eligible Death, Policy 7.1.8 may also provide further guidance.TABLE 38-4Common Infectious Exclusion Criteria for Organ Donors[\*](#tf0010){ref-type="table-fn"}Active, uncontrolled or undiagnosed infectious diseasesUnknown infection of central nervous system (encephalitis, meningitis)Herpes simplex encephalitis or other encephalitisJC virus infectionWest Nile virus infectionRabiesCJD or variant CJDOther fungal or viral encephalitisCryptococcal infection of any siteUntreated bacterial meningitis (proof of cure)Infection with HIV (serological or molecular)Active viremia: herpes, acute EBV (mononucleosis)Serological or molecular evidence of HTLV-I/II[\*](#tf0010){ref-type="table-fn"}Active hepatitis A, B, C[\*](#tf0010){ref-type="table-fn"}Active infection with *Leishmania*, *Strongyloides*, *Toxoplasmosis*, or malariaLatent or active *Trypanosoma cruzi* (Chagas disease) infectionActive tuberculosisSARSUntreated pneumoniaUntreated bacterial or fungal sepsis (e.g., candidemia)Untreated syphilisMultisystem organ failure due to overwhelming sepsis, gangrenous bowel[^4][^5]

Recipient-Derived Exposures {#s0025}
---------------------------

Infections in recipient-derived exposures are generally latent infections activated in the setting of immune suppression. It is necessary to obtain a careful history of travel and exposures to guide preventive strategies and empiric therapies. Notable among these infections are TB, strongyloidiasis, viral infections (herpes simplex virus \[HSV\] and varicella zoster or shingles), histoplasmosis, coccidioidomycosis, hepatitis B or C, and human immunodeficiency virus (HIV). Vaccination status should be evaluated (tetanus, hepatitis B, varicella and varicella zoster, childhood vaccines, influenza, pneumococcal vaccine). Dietary habits should also be considered, including the use of well water (*Cryptosporidia*), uncooked meats (*Salmonella, E. coli, Campylobacter*), and unpasteurized dairy products and luncheon meats (*Listeria*).

Community Exposures {#s0030}
-------------------

Common exposures in the community are often related to ingestion of contaminated food and water, exposure to infected children or coworkers, or exposures due to hobbies (gardening), travel, or occupation. Respiratory virus infections due to influenza, respiratory syncytial virus, and adenoviruses increase the risk for both viral pneumonia and subsequent bacterial superinfection. Community (and solid-organ or transfusion-associated) exposures to CMV and EBV may produce severe primary infection in the nonimmune host. Recent and remote exposures to endemic, geographically restricted systemic mycoses (*Blastomyces dermatitidis, Coccidioides immitis,* and *Histoplasma capsulatum)* and *Mycobacterium tuberculosis* can result in localized pulmonary, extrapulmonary, or disseminated infections. Asymptomatic *S. stercoralis* infections may reactivate decades after initial exposure in the setting of immunosuppressive therapy. Such reactivation can result in either a gastrointestinal illness with parasite migration and hyperinfestation syndrome (characterized by hemorrhagic enterocolitis, hemorrhagic pneumonia, or both) or disseminated infection with accompanying (usually) gram-negative bacteremia or meningitis. Gastroenteritis due to *Salmonella* species, *Campylobacter jejuni*, and a variety of enteric viruses can result in more severe and prolonged diarrheal disease with persistent infection and an increased risk of translocation into the bloodstream and metastatic infection.

Nosocomial Exposures {#s0035}
--------------------

Nosocomial infections are of increasing importance because organisms with significant antimicrobial resistance predominate in many centers. These include vancomycin, linezolid and quinupristin/dalfopristin-resistant enterococci, methicillin-resistant staphylococci (MRSA), and fluconazole-resistant *Candida* species. Excessive antimicrobial use has resulted in increased rates of *Clostridium difficile* colitis. Outbreaks due to *Legionella* species have been associated with hospital plumbing and contaminated water supplies or ventilation systems. Nosocomial spread of *Pneumocystis jiroveci* between immunocompromised patients has also been suggested by a variety of case series. Respiratory viral infections may be acquired from medical staff and should be considered among the causes of fever and respiratory illness among hospitalized or institutionalized, immunocompromised individuals. Influenza vaccination of staff members may decrease transmission to immunocompromised hosts. Each nosocomial infection should be investigated to ascertain the source and prevent subsequent infections.

Net State of Immunosuppression {#s0040}
------------------------------

The net state of immunosuppression is a measure of all of the factors contributing to the patient\'s risk for infection (see [Table 38-2](#t0015){ref-type="table"}). Among these are:1.The specific immunosuppressive therapy, including dose, duration, and sequence of agents2.Technical problems from the transplant procedure, resulting in leaks (blood, lymph, urine) and fluid collections, devitalized tissue, poor wound healing, and the use of surgical drainage catheters for prolonged periods3.Prolonged airway intubation4.Prolonged use of broad-spectrum antibiotics5.Renal and/or hepatic dysfunction6.Prolonged use of vascular access or dialysis catheters7.Presence of infection with one of the immunomodulating viruses, including CMV, EBV, hepatitis B (HBV) or C (HCV), or HIV.

Specific immunosuppressive agents are associated with increased risk for certain infections ([Table 38-5](#t0030){ref-type="table"} ). Combinations of these agents may enhance this risk or cause toxicity (e.g., nephrotoxicity) and may further enhance risk.TABLE 38-5Specific Immunosuppressive Drugs and InfectionAntilymphocyte globulins (lytic) and alloimmune response: Activation of latent (herpes) virus, fever, cytokine releasePlasmapheresis: Encapsulated bacteria, activation of latent CMVCostimulatory blockade: Altered memory T-cell responsesCorticosteroids: Bacteria, PCP, hepatitis B, CAzathioprine: Neutropenia, papilloma virus?MMF: Early bacterial infection, B-cells, late CMVCalcineurin inhibitors (cyclosporine/tacrolimus): Enhanced viral replication (absence of immunity), gingival infection, intracellular pathogensSirolimus: Excess infections in combination with current agents[^6]

Timetable of infection {#s0045}
======================

As immunosuppressive regimens have become more standardized, the most common infections that tend to occur in a somewhat predictable pattern depending on the time elapsed since transplantation ([Figure 38-1](#f0010){ref-type="fig"} ). This is a reflection of the changing risk factors that influence infection, including surgery and hospitalization, immune suppression, acute and chronic rejection, emergence of latent infections, and exposures to novel community infections.[@bb0025] The pattern of infections will be changed with alterations in the immunosuppressive regimen (pulse dose steroids or intensification for graft rejection), intercurrent viral infection, neutropenia (drug toxicity), graft dysfunction, or significant epidemiological exposures (travel or food).FIGURE 38-1The timeline of posttransplantation infections.(Adapted from J.A. Fishman, Infection in solid-organ transplant recipients, N.Engl. J. Med. 357 \[25\] \[2007\] 2601--2614.) *HBV*, hepatitis B virus; *HIV*, human immunodeficiency virus; *HSV*, herpes simplex virus; *LCMV*, lymphocytic choriomeningitis virus; *MRSA*, methicillin-resistant *staphylococcus aureus*; *PCP*, *Pneumocystis jiroveci* pneumonia; *PML*, progressive multifocal leukoencephalopathy; *PTLD*, posttransplantation lymphoproliferative disorder; *SARS*, severe acute respiratory syndrome; *VRE*, vancomycin-resistant *Enterococcus faecalis;*; and *VZV*, varicellazoster virus.

The timeline reflects the following three overlapping periods of risk for infection: 1) the perioperative period to approximately 4 weeks after transplantation, 2) the period 1 to 6 months after transplantation (depending on the rapidity of taper of immune suppression and the type and dosing of antilymphocyte "induction" that may persist), and 3) the period beyond the first year after transplantation. These periods reflect the evolving major risk factors associated with infection, with surgery and technical complications, followed by the intensive immune suppression with viral activation, and subsequently the community-acquired exposures with the return of normal activities.

The timeline may be used in a variety of ways: to establish a differential diagnosis for the transplantation patient suspected of having infection; as a clue to the presence of an excessive environmental hazard for the individual, either within the hospital or in the community; and as a guide to the design of preventive antimicrobial strategies. Infections occurring outside the usual period or of unusual severity may suggest either excessive epidemiological hazard or excessive immunosuppression. The prevention of infection must be linked to the risk for infection at various times after transplantation. Routine preventive strategies from the Massachusetts General Hospital, Boston, are outlined in [Table 38-6](#t0035){ref-type="table"} . It should be noted that such strategies serve only to delay the onset of infection in the face of epidemiological pressure. The use of antibiotic prophylaxis, vaccines, and behavioral modifications (e.g., routine handwashing or advice against digging in gardens without masks) may only result in a shift to the right of the infection timeline, unless the intensity of immune suppression is reduced or immunity develops.TABLE 38-6Renal Transplantation Antimicrobial Prophylaxis Protocols at the Massachusetts General Hospital, BostonA. Anti-PCP and General Antibacterial ProphylaxisBackground: Low dose TMP-SMX prophylaxis (in adults: 1 single strength per day orally) is well-tolerated and essentially eradicates *Pneumocystis* infection from this patient population; it also helps prevent other infections such as urinary tract infection, nocardiosis and listeriosis, toxoplasmosis, and a variety of gastrointestinal and pulmonary infections.Regimen: One single strength TMP-SMX tablet (containing 80 mg trimethoprim, 400 mg sulfamethoxazole) orally at bedtime for a minimum of 4-6 months posttransplantation. One double strength tablet three times a week may also be used. Patients infected with CMV, with chronic rejection, or recurrent infections may be maintained on longer or lifelong prophylaxis. For those patients proven to not tolerate TMP-SMX, alternative regimens include: 1) a combination of atovaquone 1500 mg orally with meals once daily, plus levofloxacin (or equivalent fluoroquinolone without antianaerobic spectrum) 250 mg once daily to help prevent other non-PCP infections; 2) pentamidine (300 mg IV or inhaled every 3-4 weeks); and 3) Dapsone (100 mg orally daily). Each of these agents has toxicities that must be considered, including hemolysis in G6PD-deficient hosts with dapsone and methemoglobinemia. None of these alternative programs offer the same broad protection of TMP-SMX.B. Herpes Group Virus PreventionThe human herpes viruses (\[CMV\], \[HSV-1 and HSV-2\], \[EBV\], \[VZV\], \[HHV-6\], \[HHV-7\] and \[HHV-8/Kaposi sarcoma-associated herpes virus\]) are among the most important causes of infectious disease morbidity and mortality in the transplant recipient. Different regimens are determined by the clinical risk, the major determinants of which are the past experience of donor and recipient with the virus (as defined by the presence or absence of circulating antibody prior to transplant) and the nature of the immunosuppressive therapy.Regimen for Herpes prophylaxisCytolytic Transplant (Thymoglobulin, OKT3, etc.)Donor CMV AntibodyRecipient CMV AntibodyProphylaxisMonitoring with CMV AntigenemiaYes+−Valcyte × 6 mosTeam may wish to monitor if clinically indicated by symptoms−+++−−+−ACV/Famvir/ValACV 6 mos[\*](#tf0020){ref-type="table-fn"}No−+Valcyte × 3 mosTeam may wish to monitor if clinically indicated by symptoms−+++−−ACV/Famvir/ValACV 3 mos[\*](#tf0020){ref-type="table-fn"}Generic NameTrade NameGFR \>60GFR 40-59GFR 25-39GFR 10-24ValganciclovirValcyte900 mg a day450 mg a day450 mg every 2 days450 mg twice a weekAcyclovir[\*](#tf0020){ref-type="table-fn"}Zovirax400 mg po tid[@bb0180]400 mg po bid[@bb0180]400 mg po bid[@bb0180]200 mg po tid[@bb0180]Famciclovir[\*](#tf0020){ref-type="table-fn"}Famvir500 mg po q day250 mg a day250 mg a day250 mg every 2 daysValacyclovir[\*](#tf0020){ref-type="table-fn"}Valtrex500 mg po bid[@bb0180]500 mg po q day[@bb0180]500 mg po q day[@bb0180]500 mg po every 2 days[@bb0180]C. Anti-*Candida* ProphylaxisPrevention of mucocutaneous infection can be accomplished with oral clotrimazole (may increase calcineurin inhibitor levels) or nystatin 2 to 3 times per day at times of steroid therapy or in the face of antibacterial therapy; we usually give for the first 3 to 5 days after transplantation. Fluconazole (at a dose of 200-400 mg/day for 10-14 days) is used in the treatment of prophylaxis failures. Routine prophylaxis with fluconazole for 30 days is used for pancreas transplants.[^7][^8]

Phase One: 1 to 4 Weeks after Transplantation {#s0050}
---------------------------------------------

During the first month after transplantation, three types of infection occur. The first type of infection was present in the recipient prior to transplantation; it was either unrecognized or inadequately treated, and now has emerged in the setting of surgery, anesthesia, and immunosuppression. Pretransplantation pneumonia and vascular access infections are common examples of this type of infection. Colonization of the recipient with resistant organisms is also common (e.g., MRSA). The first rule of successful transplant infectious disease control is the eradication of all active infection prior to transplantation.

The second type of early infection was present in the donor before transplantation. This is often a nosocomial-acquired organism (resistant gram-negative bacilli and *Staphylococcus aureus* or *Candida* species) due to either systemic infection in the donor (e.g., line infection) or contamination during organ procurement. The result is a high risk of infection of vascular suture lines with resultant mycotic aneurysm. Uncommonly, infections have been transmitted from donor to recipient, including TB or fungal infections (e.g., histoplasmosis) that emerge earlier in the timeline than expected (i.e., in the first month).

The third type and the most common source of infections in this early period is related to the complex surgical procedure of transplantation. These include surgical wound infections, pneumonia (aspiration), bacteremia due to vascular access or surgical drainage catheters, urinary tract infections, or infections of fluid collections (due to leaks of vascular or urinary anastomoses or lymphoceles). These are nosocomial infections and, as such, are due to the same bacteria and *Candida* infections observed in nonimmunosuppressed patients undergoing comparable surgery but with the immune suppression, the signs of infection may be subtle and the severity or duration may be greater. The technical skill of the surgeons and meticulous postoperative care (i.e., wound care, endotracheal tubes, vascular access devices, and drainage catheters) are the determinants of risk for these infections. Also among the common infections is *C. difficile* colitis. Limited perioperative antibiotic prophylaxis for renal transplantation (i.e., from a single dose to 24 hours of an antibiotic such as cefazolin) is usually adequate with additional coverage only for known risk factors (e.g., prior colonization with MRSA). For pancreas transplantation, perioperative prophylaxis against yeasts with fluconazole is commonly used, remembering the interactions between azole antifungal agents and calcineurin inhibitors and sirolimus (levels may be increased significantly).

Notable by their absence in the first month after transplantation are opportunistic infections, even though the daily doses of immunosuppressive drugs are at their highest during this time. The implications of this observation are important: The net state of immunosuppression is not great enough to support the occurrence of opportunistic infections unless an exposure has been excessive; this observation suggests that it is not the daily dose of immunosuppressive drugs that is of importance but rather the sustained administration of these drugs, the area under the curve, in determining the net state of immunosuppression. Thus, the occurrence of a single case of opportunistic infection in this period should trigger an epidemiological investigation for an environmental hazard.

Phase Two: 1 to 6 Months after Transplantation {#s0055}
----------------------------------------------

Infection in the transplant recipient 1 to 6 months after transplantation has one of three causes:1.Lingering infection from the perisurgical period, including relapsed *C. difficile* colitis, inadequately treated pneumonia, or infection related to a technical problem (e.g., urine leak, lymphocele, hematoma). Fluid collections require drainage for treatment.2.Viral infections, including CMV, HSV, shingles (VZV), human herpesvirus 6 or 7, EBV, relapsed hepatitis (HBV, HCV), and HIV. These viruses are unique: lifelong infection; tissue-associated (often transmitted with the allograft from seropositive donors); immunomodulating---systemically immune suppressive; and, potentially, predisposing to graft rejection. It is also notable that the herpesviruses are prominent because of the attenuated ability of T-cells to control these infections. Among the other viral pathogens of this period that must be included are BK polyomavirus in association with allograft dysfunction, and community-acquired respiratory viruses (adenovirus, influenza, parainfluenza, respiratory syncytial virus, metapneumovirus). The suppression of antibody production (e.g., using tacrolimus and mycophenolate mofetil or with lymphopenia) may predispose to other infections.3.Opportunistic infection due to *P. jiroveci, Listeria monocytogenes, Toxoplasma gondii, Nocardia* species*, Aspergillus* species, and other agents.

In this period, the stage is also set for the emergence of a subgroup of patients, the "chronic ne'er-do-wells"---individuals who require higher than average immune suppression to maintain graft function or who have prolonged untreated viral infections and other opportunistic infections, predicting long-term susceptibility to many other infections (third phase, discussed later). Such individuals may merit prolonged (lifelong) prophylaxis (antibacterial or antiviral, or both) to prevent life-threatening infection.

The specific opportunistic infections that occur reflect the specific immunosuppressive regimen used and the presence or absence of immunomodulating viral infection. Viral pathogens (and rejection) are responsible for the majority of febrile episodes that occur in this period. During this period, anti-CMV strategies and trimethoprim-sulfamethoxazole prophylaxis are effective in decreasing the risk of infection. Trimethoprim-sulfamethoxazole prophylaxis eliminates *P. jiroveci* pneumonia (PCP) and reduces the incidence of urinary tract infection and urosepsis, *Listeria monocytogenes* meningitis, *Nocardia* species infection, and *T. gondii* infection.

Phase Three: More than 6 to 12 Months after Transplantation {#s0060}
-----------------------------------------------------------

Transplant recipients who are more than 6 months past the procedure can be divided into three groups in terms of infection risk.

The first group consists of the majority of transplant recipients (70%-80%) who had a technically good procedure with satisfactory allograft function, reduced and maintenance immunosuppression, and absence of chronic viral infection. These patients resemble the general community in terms of infection risk, with community-acquired respiratory viruses constituting their major risk.

The second group (\~10% of patients) suffers chronic viral infection, which, in the absence of effective therapy, will lead inexorably to either end organ damage (e.g., BK polyomavirus nephropathy, cryoglobulinemia, or cirrhosis from HCV; HBV being relatively well managed at present) or malignancy (posttransplantation lymphoproliferative disease \[PTLD\] due to EBV or anogenital cancer due to papilloma viruses).

The third group of patients (\~10% of all recipients) has less than satisfactory allograft function and requires excessive amounts of immunosuppressive therapy for recurrent graft rejection. This may be associated with chronic viral infection. This is the subgroup of transplant recipients, often termed the "chronic ne'er-do-wells," who are at highest risk for opportunistic infection with such pathogens as *P. jiroveci, L. monocytogenes, Nocardia asteroides,* and *Cryptococcus neoformans*. It is our practice to give these patients lifetime maintenance trimethoprim-sulfamethoxazole prophylaxis and to consider the use of fluconazole prophylaxis. Also, this group is susceptible to organisms more often associated with immune dysfunction of acquired immune deficiency syndrome (AIDS) (*Bartonella, Rhodococcus, Cryptosporidium,* and *Microsporidium* species) and invasive fungal pathogens (*Aspergillus, Zygomycetes,* and the *Dematiaceae* or pigmented molds). Minimal clinical signs or symptoms merit careful evaluation in these vulnerable high-risk individuals.

Assessment of infectious disease risk in recipient and potential donor before transplantation {#s0065}
=============================================================================================

Guidelines for pretransplantation screening have been the subject of several recent publications including a consensus conference of the Immunocompromised Host Society (ICHS), the American Society for Transplantation (AST) Clinical Practice Guidelines on the evaluation of renal transplantation candidates, and the American Society of Transplant Physicians (ASTP) Clinical Practice Guidelines on the evaluation of living renal transplant donors.[@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050]

The Transplant Donor {#s0070}
--------------------

### Deceased Donor Evaluation {#s0075}

Time constraints are the critical feature in screening deceased donors. A useful organ may be procured and implanted before some microbiological assessments have been completed. Thus, major infections must be excluded and appropriate cultures and stored samples obtained for future reference. As a result, bacteremia or fungemia may not be detected until after the transplantation has occurred. Such infections have not generally resulted in transmission of infection as long as the infection has been adequately treated or covered by the routine antibiotic prophylaxis.[@bb0035], [@bb0040] In recipients of tissues from 95 bacteremic donors, a mean of 3.8 days of effective therapy post-transplantation appeared adequate to prevent transmission; longer courses of therapy in the recipient are preferred, targeting known potential pathogens from the donor.[@bb0055] Bacterial meningitis must also be treated with antibiotics that penetrate the cerebrospinal fluid (CSF) before procurement. Similarly, because of the limited time for testing, certain acute infections (HIV, HBV, or HCV) may be undetected in the "window" period prior to antibody formation, and many organ procurement organizations are using viral nucleic acid testing to further decrease risk of infection and expand the donor pool.[@bb0045] [@bb0050] The donor\'s clinical, social, and medical histories are essential in reducing the risk of such infections. The extent of therapy needed for focal infections in the donor outside the procured organs remains unresolved. Major exclusion criteria for donors are outlined in [Table 38-4](#t0025){ref-type="table"}.

### Living Donor Evaluation {#s0080}

The differences in screening of the living donor and the cadaver donor are largely based on the different time frames during which this screening takes place. The living donor procedure should be considered elective, thus, the evaluation should be completed and infections treated prior to such procedures. An interim history must be taken at the time of surgery to assess the presence of new infections since the initial donor evaluation. Intercurrent infections (flulike illness, headache, confusion, myalgia, and cough) might be the harbinger of important infection (West Nile Virus, severe acute respiratory syndrome \[SARS\], rabies, *Trypanosoma cruzi*). Live donors undergo a battery of serological tests (see [Table 38-3](#t0020){ref-type="table"}) and an evaluation for latent TB and, if indicated, a chest radiograph. The testing must be individualized, based on unique risk factors and exposures. Of particular importance to the renal transplant recipient is the exclusion of urinary tract infection.

Special Considerations in Organ Procurement {#s0085}
-------------------------------------------

### Mycobacterium tuberculosis {#s0090}

Transmission of donor *M. tuberculosis* represented approximately 4% of reported posttransplantation TB cases in a review of 511 patients by Singh and colleagues.[@bb0060] Active disease should be excluded in purified protein derivative (PPD) positive donors, including chest radiograph, sputum cultures, and chest computed tomography (CT), if the chest radiograph is abnormal. Urine AFB cultures may be useful in the PPD-positive kidney donor. Isoniazid prophylaxis of the recipient should be considered for untreated, PPD-positive donors, especially with donors who are from endemic regions, who use a high-dose steroid regimen, or who are from high-risk social environments.[@bb0065]

### Chagas Disease (*T. cruzi*) {#s0095}

This parasitic disease has been transmitted by transplantation in endemic areas and recently in the United States,[@bb0015] more commonly after heart transplantation, although it can be transmitted with other organs and blood products. Schistosomiasis and infection by *S. stercoralis* are generally recipient-derived problems.

### Viral Infections other than Cytomegalovirus {#s0100}

Viral infections are the most common cause of donor-derived infection and can lead to significant graft dysfunction, morbidity, and mortality. Standard pretransplantation testing includes a panel for numerous viruses; many other unsuspected viruses, including zoonotic viruses, have been unwittingly transmitted during organ transplantation.[@bb0055] Donors who are considered high-risk are being used more frequently as a means to expand the organ pool. The transplant team should discuss the risks and benefits with each recipient and include this information in the informed consent. Posttransplantation testing with nucleic acid testing should be done 1 to 3 months after transplantation; serological testing has a higher false-negative rate.

Most adult donors are infected with latent EBV. The risk for PTLD is greatest in the EBV seronegative recipient of an EBV seropositive allograft. PTLD is most common in pediatric transplant recipients and in adults coinfected with active CMV or on higher levels of immune suppression. Monitoring after transplantation should be considered for at-risk individuals, using a quantitative, molecular assay (e.g., polymerase chain reaction \[PCR\]) for EBV.

Hepatitis B surface antigen (HBsAg) and HBV core antibody (HBcAb) are used to screen for HBV, with HBsAb positivity indicating either vaccination or prior infection. The HBsAg negative, HBcAb-immunoglobulin G (IgG) positive donor may have viral DNA in the liver (or maybe be a false-positive) but may be appropriate as a donor.[@bb0060] [@bb0065] Quantitative molecular assays for HBV can be obtained after transplantation for monitoring. HBV vaccination of the recipient prior to transplantation may help protect them against active disease after receiving an HBcAb positive organ. Of note, HBcAb-positive recipients are at higher risk for HBV reactivation after renal transplantation and should be monitored or possibly given antiviral medication.[@bb0070]

HCV infection will generally progress more rapidly with immune suppression. HCV seropositive renal transplant candidates are more likely to develop cirrhosis and complications of liver failure. Seropositive donors are usually deferred, except occasionally in the setting of a seropositive recipient with HCV genotype 1 (the other genotypes have less risk of serious illness, and superinfection with genotype 1 is likely to cause worse disease).

HIV-infected donors have not been used except occasionally for HIV infected recipients. The progression of disease is rapid and outweighs the benefits of transplantation. Donors may be excluded based on historic evidence of high-risk behavior for HIV infection.[@bb0075] The use of nucleic acid testing prior to transplantation may help us expand the donor pool.[@bb0045] [@bb0050]

Human T lymphotropic virus I (HTLV-I) is endemic in the Caribbean and parts of Asia (Japan) and can progress to HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or to adult T-cell leukemia/lymphoma (ATL).[@bb0080] HTLV-II is similar to HTLV-I serologically but is less clearly associated with disease. Use of organs from such donors is generally avoided, although not all organ procurement organizations test for this virus; it is not known if immunosuppression has an impact on risk of progression to leukemia/lymphoma. Progression to ATL after use of seropositive living donor organs has been reported.[@bb0080]

West Nile virus (WNV) is a flavivirus associated with viral syndromes and meningoencephalitis and may be transmitted by blood transfusion and organ transplantation.[@bb0085] Routine screening of donors is done by some organ procurement organizations in endemic areas. Donors with unexplained changes in mental status or recent viral illness with neurological signs should be avoided.

### Recipient Screening {#s0105}

The pretransplantation period is useful for a thorough travel, animal, and environmental and exposure history; updating immunizations; and counseling of the recipient regarding travel, food, and other infection risks. Ongoing infection must be eradicated prior to transplantation. Two forms of infection pose a special risk:1.Active bacterial infections: Bloodstream infections may be related to vascular access, including that for dialysis and pneumonia, which puts the patient at high risk for subsequent lung infection with nosocomial organisms. Infected ascites or peritoneal dialysis fluid must also be cleared prior to surgery. Urinary tract infection (UTI) must be eliminated prior to transplantation with antibiotics with or without nephrectomy. Similarly, skin disease that threatens the integrity of this primary defense against infection should be corrected before transplantation, even if doing so requires the initiation of immunosuppression prior to transplantation (e.g., the initiation of immune suppression to treat psoriasis or eczema). Finally, the history of more than one episode of diverticulitis should initiate an evaluation to determine whether sigmoid colectomy should be carried out prior to transplantation.2.Tuberculosis: The incidence of reactivation disease due to *M. tuberculosis* is far higher in the transplant recipient than in the general population. Patients with end-stage renal disease are more likely to be anergic and have a false-negative PPD. In a cohort of 118 subjects on hemodialysis, 41 (35%) were PPD-positive and 77 (65%) were negative, of which 62 (81%) were anergic.[@bb0090] The newly developed interferon-gamma-based QuantiFERON-TB Gold test (Cellestis, Chadstone, Victoria, Australia) may be helpful in diagnosing some additional cases of latent tuberculosis in this setting, and may help distinguish those who have true latent TB from those who are PPD positive due to prior vaccination with Bacille Calmette-Guerin (BCG). Recent work suggests that for optimal diagnostic accuracy, this test should be done before, rather than after, hemodialysis.[@bb0095] Active tuberculosis must be treated prior to transplantation. Latent tuberculosis should be treated either before or at the time of transplantation. The major antituberculous drugs are potentially hepatotoxic, and significant drug interactions are common between the antituberculosis agents and the agents of immune suppression (especially the rifamycins).

Pretransplantation screening for other latent infections such as *Strongyloides, Schistosoma, Coccidioides,* and *Histoplasma* in recipients with the right epidemiology may allow for the clinical team to target prophylaxis more effectively, or reach a diagnosis more rapidly. The pretransplantation evaluation may also allow for better vaccination, such as in those who are seronegative for hepatitis A and B, mumps, measles, rubella, and varicella.

Selected infections of importance {#s0110}
=================================

General Considerations {#s0115}
----------------------

The spectrum of infection in the immunocompromised host is quite broad. Given the toxicity of antimicrobial agents and the need for rapid interruption of infection, early, specific diagnosis is essential in this population. The need for invasive diagnostic tools cannot be overemphasized. Advances in diagnostic modalities (CT or magnetic resonance imaging \[MRI\] scanning and molecular microbiological techniques) may greatly assist in this process. Given the diminished immune responses of the host and the frequency of multiple simultaneous processes, invasive diagnosis is often the best method for optimal care. The initial therapy may, by necessity, be broad with a rapid narrowing of the antimicrobial spectrum as data become available. Reduction in the intensity of immune suppression is a cornerstone of treatment of active infection, balancing risks of the infection with graft rejection. The selection of the specific agent to reduce may depend upon the organisms isolated. Similarly, reversal of some immune deficits (neutropenia, hypogammaglobulinemia) may be possible with adjunctive therapies (colony stimulating factors or intravenous immunoglobulin). Viral coinfection (CMV, EBV) is common and merits additional therapy.

Viral Pathogens {#s0120}
---------------

### Cytomegalovirus {#s0125}

CMV is the single most important pathogen in transplant recipients and has a variety of direct and indirect effects.[@bb0025] [@bb0100] The direct effects include:•Fever and neutropenia syndrome with possible hepatitis, nephritis, leukopenia, and/or thrombocytopenia•Pneumonia•Gastrointestinal invasion with colitis, esophagitis, gastritis, ulcers, bleeding, or perforation•Hepatitis, pancreatitis, chorioretinitis

With the exception of chorioretinitis, the direct clinical manifestations of CMV infection usually occur 1 to 4 months after transplantation in the absence of prophylaxis; chorioretinitis is rare after renal transplantation and usually does not begin until later in the transplantation course.

The *indirect effects* of active CMV disease are very important; this term describes the effects of CMV on the host immune system and sequelae thereof. CMV disease produces a profound suppression of a variety of host defenses, resulting in an increase in the net state of immunosuppression, further predisposing the host to secondary invasion by such pathogens as *P. jiroveci, Candida* and *Aspergillus* species, and some bacterial infections.[@bb0105] CMV also contributes to the risk for graft rejection, PTLD, human herpesvirus 6 (HHV-6), and human herpesvirus 7 (HHV-7) infections.

The association between kidney rejection and CMV infection in renal allograft recipients was demonstrated more than a decade ago.[@bb0110] [@bb0115] Seronegative recipients of renal transplants from seropositive donors showed a 50% reduction in organ rejection when given antiviral CMV prophylaxis compared to placebo.[@bb0120] CMV prophylaxis is associated with less rejection and significant improvements in graft and patient survival in donor-positive, recipient-negative (D+/R-) deceased-donor kidney recipients at 3 years.[@bb0125]

The mechanisms by which CMV causes allograft damage are complex and remain unknown. Possible mechanisms include increased antigen processing and presentation associated with the major histocompatibility complex (MHC); altered expression of proinflammatory growth factors, chemokines, and cytokines; altered T-cell subsets; upregulation of proinflammatory adhesion molecules; modulation of the nitric oxide synthase pathway; induction of intracellular reactive oxygen species in vascular smooth muscle cells; and procoagulant activity via antithrombin III and fibrinogen.[@bb0025] [@bb0130], [@bb0135], [@bb0140]

#### Patterns of Transmission {#s0130}

Transmission of CMV in the transplant recipient occurs in one of three patterns: primary infection, reactivation infection, and superinfection.[@bb0025]

Primary infection occurs when seronegative individuals receive grafts from latently infected, seropositive donors (D+/R-), with subsequent activation of the virus and systemic dissemination after transplantation. Between 40% and 50% of these patients experience direct infectious disease manifestations of CMV while the majority are viremic, often without symptoms. Primary CMV infection may also occur in seronegative individuals after transfusion or sexual contacts in the community; such disease may be severe.

In reactivation infection, seropositive individuals reactivate endogenous virus after transplantation (donor seropositive or seronegative, recipient seropositive \[D+/R+ or D-/R+\]). When conventional immunosuppressive therapy is used (without antilymphocyte antibody treatment), about 10% to 15% experience direct infectious disease syndromes; higher rates (up to 50%) are seen with the use of induction antilymphocyte therapy.

Superinfection with CMV also can occur. Various genotypes of CMV exist; in a recent survey, gB1 was the predominant single genotype (50.4%), followed by gB2 (21%), gB3, (9%), and gB4 (3%), and mixed-genotype infections were seen in 17% with much higher viral loads noted.[@bb0145] The viral genotype or genotypes causing active disease in the setting of an allograft from a seropositive donor transplanted into a seropositive recipient remains to be elicited.

#### Pathogenesis {#s0135}

Control of CMV infection is via MHC-restricted, virus-specific, cytotoxic T lymphocyte response controlled by CD4+ lymphocytes. Seroconversion has been used as a predictor for the development of host immunity. QuantiFERON-CMV is an emerging diagnostic assay for the detection of interferon (IFN)-gamma in response to CMV CD8+ T-cell epitopes and may be a useful clinical tool for monitoring the immune response in immunosuppressed patients during therapy.[@bb0150] The major effector for activation of virus is the nature of the immunosuppressive therapy being administered. The antilymphocyte antibodies, both polyclonal and monoclonal, are direct activators of viral infection (mimicking the alloimmune response) and also provoke the elaboration of tumor necrosis factor (TNF) and the other proinflammatory cytokines that enhance viral replication. Cyclosporine, tacrolimus, sirolimus, and prednisone (other than pulse doses) have limited ability to reactivate latent CMV while azathioprine, mycophenolate, and cyclophosphamide are moderately potent in terms of promoting viral reactivation. Allograft rejection is a major stimulus for CMV activation and vice versa. CMV infection has been linked to a diminished outcome of renal and other allografts, as described above.

#### Diagnosis {#s0140}

Careful clinical management of CMV, both prevention and treatment, is of great importance for the transplant recipient. CMV cultures are generally too slow and insensitive for clinical use. A positive CMV culture (or shell vial culture) derived from respiratory secretions or urine is of little diagnostic value, since many patients secrete or shed CMV in the absence of invasive disease. Serological tests are useful prior to transplantation to predict risk but are of little value after transplantation in defining clinical disease (this statement includes measurements of anti-CMV IgM levels). Seroconversion in transplantation is generally delayed and thus not useful for clinical diagnosis. Seroconversion to CMV is evidence that that the patient has been exposed to CMV and has developed some degree of immunity. Serologies may be confounded by recent administration of blood products. The demonstration of CMV inclusions in tissues in the setting of a compatible clinical syndrome is the gold standard for diagnosis.

Two types of quantitative assays have been developed: the nucleic-acid based molecular assays and the antigen detection assays. The molecular assays are highly specific and sensitive for the detection of viremia. The antigenemia assay is a semiquantitative fluorescent assay in which circulating neutrophils are stained for CMV early antigen (pp65), which is taken up nonspecifically as a measure of the total viral burden in the body. The molecular and antigenemia assays cannot be directly compared; caution should be used when comparing similar assays done in different laboratories, as there can be significant interlaboratory variation. Either assay can be used in management. The highest viral loads (or antigenemias) are often associated with tissue-invasive disease, with lower levels found with asymptomatic CMV infection, and variable loads in the CMV syndrome.

Quantitation of the intensity of CMV infection has been linked to the risk for infection in transplant recipients.[@bb0155] The advent of quantitative assays for the diagnosis and management of CMV infection has allowed noninvasive diagnosis in many patients with two important exceptions: neurological disease, including chorioretinitis; and gastrointestinal disease, including invasive colitis and gastritis. In these syndromes, the CMV assays may be negative and invasive (biopsy) diagnosis may be needed.

The central role of assays is illustrated by the approach to prevention of CMV (see [Table 38--6](#t0035){ref-type="table"}). The schedule for screening is linked to the risk for infection. Thus monthly screening is performed in the high risk patient after the completion of prophylaxis to screen for late-onset infection for 3 to 6 months. In the patient being treated for CMV infection, the assays provide an end point (zero positivity) for therapy and the initiation of prophylaxis. In the event that clinical resistance develops while on appropriate treatment with ganciclovir, genotyping by molecular diagnostic assay is commercially available with a rapid turn-around time (especially compared to previous culture-based assays) and may provide further guidance as to the optimal therapy.[@bb0155]

#### Cytomegalovirus Prevention {#s0145}

Prevention of CMV infection must be individualized for immunosuppressive regimens and the patient. Two strategies commonly used for CMV prevention are the following: 1) universal antiviral prophylaxis; and 2) preemptive therapy. Universal prophylaxis involves giving antiviral therapy to all at-risk patients beginning at or immediately posttransplantation for a defined time period. In preemptive therapy, quantitative assays are used to monitor patients at predefined intervals (often every week) to detect early disease. Positive assays result in therapy. Preemptive therapy incurs extra costs for monitoring and coordination of outpatient care while reducing the cost of drugs and the inherent toxicities. Universal prophylaxis has the possible advantage of preventing not only CMV infection during the period of greatest risk, but also diminishing infections due to HHV6, HHV7, and EBV. Further, the indirect effects of CMV (i.e., graft rejection, opportunistic infection) may also be reduced by routine prophylaxis. In practice, neither strategy is perfect. Both breakthrough disease and ganciclovir resistance have been observed in both approaches.

Given the risk for invasive infection, patients at risk for primary infection (CMV D+/R-) tend to be given prophylaxis for 3 to 6 months after transplantation. We use 6 months of prophylaxis in patients receiving lytic antilymphocyte antibodies such as thymoglobulin. Other groups are candidates for preemptive therapy if an appropriate monitoring system is in place and patient compliance is good. Prophylaxis is achieved with 50% of the therapeutic dose of ganciclovir or valganciclovir (corrected for renal function). The dose of antiviral prophylaxis should not be reduced for neutropenia.

#### Treatment {#s0150}

The standard of care for treating CMV disease had been 2 to 3 weeks of intravenous ganciclovir (5 mg/kg twice daily, with dosage adjustments for renal dysfunction). New data suggests that oral valganciclovir, which has a bioavailability of 60%, may be used to treat mild to moderate disease.[@bb0160] [@bb0165] Relapse does occur, primarily in those not treated beyond the achievement of a negative quantitative assay. Therefore, we treat intravenously until viremia has been cleared and follow it with prophylaxis with 1 to 3 months of oral ganciclovir (1 g two or three times daily) or valganciclovir (based on creatinine clearance). This approach has resulted in rare symptomatic relapses and appears to prevent the emergence of antiviral resistance.

A number of issues remain. Some relapses occur in gastrointestinal (GI) disease because the blood assays used to follow disease are not reliable in this setting. Thus, repeat endoscopy should be considered to assure the clearance of infection. The optimum dosing of valganciclovir for prophylaxis in renal transplant recipients is also unclear. Many centers use 450 mg/day orally (given reduced creatinine clearance), although the U.S. Food and Drug Administration (FDA) has approved a dose of 900 mg/day. It may be worth measuring the creatinine clearance to ensure appropriate dosing. We have seen cases of resistance with better-than-expected renal function and lower doses of valganciclovir.

Alternative therapies are available in intravenous form only. These include foscarnet and cidofovir. Foscarnet has been used extensively for therapy of CMV in AIDS patients. It is active against most ganciclovir-resistant strains of CMV. We sometimes use combination therapy (ganciclovir and foscarnet) for such individuals, given the toxicities of each agent and the antiviral synergy demonstrated.[@bb0170] Cidofovir has been used in renal transplantation recipients, often with nephrotoxicity; isolates that are resistant to ganciclovir are more likely to also be resistant to cidofovir than foscarnet. Both foscarnet and cidofovir may exhibit synergistic nephrotoxicity with calcineurin inhibitors. A newer class of agents (leflunomide) has been approved for immune suppression and treatment of rheumatological diseases and may have useful activity against CMV (and possibly BK polyomavirus).[@bb0175]

### Varicella Zoster {#s0155}

Most adult renal transplant recipients were previously infected with VZV and are at risk for reactivation infection (shingles or zoster).[@bb0180] Occasional cases of widely disseminated, life-threatening disease are seen. Viral prophylaxis in the first 3 to 6 months after solid organ transplantation may help protect transplant recipients during their most vulnerable time. Previously nonimmune recipients are at risk for severe community-acquired primary disease. Both the varicella and zoster vaccines are live viral vaccines that are generally contraindicated in immunosuppressed hosts.[@bb0185]

#### Diagnosis {#s0160}

The rashes of HSV-1/2 and varicella zoster can be clinically similar in certain locations, and it is important to distinguish between them. Skin scrapings or biopsies may be sent for cultures or immunohistochemistry analysis, or both, which can identify the specific virus. Serology is not helpful in the acute setting, except to confirm that someone may have reactivation disease.

#### Treatment {#s0165}

Treatment of HSV-1/2 infection involves lower doses of renally-adjusted acyclovir, while zoster requires higher doses of either valacyclovir (1 g three times a day, renally adjusted) or intravenous acyclovir for disseminated or significant multi-dermatomal disease. Post-herpetic neuralgia can be very debilitating and may require further medications; guidelines on management can be helpful.[@bb0190] In general, acute disease with varicella zoster may serve to "vaccinate" the host. The live, viral vaccine has no part in acute management, nor should it be given to immunocompromised hosts.

### Epstein-Barr Virus {#s0170}

EBV is a ubiquitous herpesvirus with which the majority of adults are infected. EBV primarily infects B lymphocytes. In immunosuppressed transplant recipients, primary EBV infection (and relapses in the absence of antiviral immunity) causes a mononucleosis-type syndrome, generally presenting as a lymphocytosis (B-cells) with or without lymphadenopathy or pharyngitis. Meningitis, hepatitis, and pancreatitis may also be observed. Remitting-relapsing EBV infection is common in children and may reflect the interplay between evolving antiviral immunity and immune suppression. This syndrome may suggest relative overimmune suppression and may lead to PTLD,[@bb0195] since EBV plays a central role in the pathogenesis of PTLD. The most clearly defined risk factor for PTLD is primary EBV infection that increases the risk for PTLD by 10-fold to 76-fold. PTLD may occur, however, in the absence of EBV infection or in seropositive patients. Posttransplantation non-Hodgkin lymphoma (NHL) is a common complication of solid organ transplantation. Lymphomas comprise up to 15% of tumors among adult transplant recipients (51% in children) with mortality of 40% to 60%. Many deaths are associated with allograft failure after withdrawal of immune suppression during treatment of malignancy. Compared to the general population, PTLD has increased extranodal involvement, poor response to conventional therapies, and poor outcomes. The spectrum of disease ranges from benign polyclonal, B-cell infectious mononucleosis like disease to malignant, monoclonal lymphoma.[@bb0195] The majority is of B-cell origin, although T-cell, natural killer-cell and null cell tumors are described. It should be noted that T-cell PTLD has been demonstrated in allografts and confused with graft rejection or other viral infection. Late PTLD (more than 1-2 years after transplantation) is more often EBV-negative in adults.

The clinical presentations of EBV-associated PTLD are protean and may include:1.Unexplained fever2.A mononucleosis-type syndrome, with fever, malaise, with or without pharyngitis or tonsillitis (occasionally diagnosed incidentally in tonsillectomy specimens, especially in children); lymphadenopathy may not be observed.3.Gastrointestinal bleeding, obstruction, perforation4.Abdominal mass lesions5.Infiltrative disease of the allograft6.Hepatocellular or pancreatic dysfunction7.Central nervous system disease

#### Diagnosis {#s0175}

Quantitative EBV viral load testing is required for the diagnosis and management of PTLD.[@bb0200] [@bb0205] Serological testing is not useful for the diagnosis of acute EBV infection or PTLD in transplantation. Serial assays are more useful in an individual patient than specific viral load measurements. These assays are not standardized and cannot be directly compared between different laboratories. In general, the pathological diagnosis is otherwise similar as for other types of lymphoma. Special immunohistochemistry stains for EBV can sometimes be helpful. Gene rearrangement studies can also be useful, especially for the rarer lymphomas.[@bb0200]

#### Management {#s0180}

Clinical management depends on the stage of disease. In the polyclonal form, particularly in children, establishment or augmentation of immune function may suffice to cause PTLD to regress. Reduction of immunosuppression remains the mainstay of first-line treatment; accumulating evidence supports the role of rituximab as second-line therapy with cytotoxic chemotherapy reserved for specific circumstances.[@bb0210]

### Polyomaviruses {#s0185}

Polyoma viruses have been identified in transplant recipients in association with nephropathy and ureteral obstruction (BK virus, BKV) and in association with demyelinating disease of the brain (JC virus, JCV) similar to that in AIDS.[@bb0215], [@bb0220], [@bb0225], [@bb0230], [@bb0235], [@bb0240] Polyoma viruses are small nonenveloped viruses with covalently closed, circular, double-stranded DNA genomes. Adult levels of seroprevalence are 65% to 90%.[@bb0245] BK virus appears to achieve latency in renal tubular epithelial cells. JC virus has also been isolated from renal tissues but appears to have preferred tropism for neural tissues.[@bb0250] Reactivation occurs with immune deficiency, suppression, and tissue injury (e.g., ischemia-reperfusion).

#### BK Polyoma Virus Infection {#s0190}

BK virus is associated with a range of clinical syndromes in immunocompromised hosts: viruria and viremia, ureteral ulceration and stenosis, and hemorrhagic cystitis particularly in recipients of bone marrow transplantation (BMT).[@bb0205] [@bb0210] [@bb0225] [@bb0230] Active infection of renal allografts has been associated with progressive loss of graft function (BK nephropathy) in 3% to 10% of renal transplantation patients.[@bb0225] This may be referred to as polyoma virus-associated nephropathy (PVAN). BK nephropathy is rarely recognized in recipients of nonrenal organs.[@bb0230] The clinical presentation of disease is usually as sterile pyuria, reflecting shedding of infected tubular and ureteric epithelial cells. These cells contain sheets of viruses and are detected by urine cytology as *decoy cells*.[@bb0225] Some patients present with diminished renal allograft function or, rarely, with ureteric stenosis and obstruction. In such patients, the etiologies of decreased renal function must be carefully evaluated (e.g., mechanical obstruction, drug toxicity, pyelonephritis, rejection, thrombosis, active infection, or recurrent disease). The choice of treatment is to either increase immune suppression to treat suspected graft rejection or reduce immune suppression to allow the immune system to control infection. Patients with BK nephropathy treated with increased immune suppression have a high incidence of graft loss associated with further reactivation of the BK virus. Reduced immune suppression may stabilize viral activation, but risks graft rejection. Polyoma-associated nephropathy manifested by characteristic histological features and renal dysfunction is found in about 1% to 8% of renal transplant patients.[@bb0255]

Risk factors for nephropathy are poorly defined. Hirsch et al.[@bb0220] ^,^ [@bb0260] found that cellular rejection occurred more commonly in patients with BK nephropathy than in controls. Other studies have implicated high dose immunosuppression (particularly tacrolimus and mycophenolate mofetil),[@bb0265] pulse dose steroids, severe ischemia-reperfusion injury, exposure to antilymphocyte antibody therapy, an increased number of human leukocyte antigen mismatches, cadaver renal transplants, and the presence and degree of viremia in the pathogenesis of disease.[@bb0225] [@bb0230] The intensity of immunosuppression is a major risk factor. However, the role of a specific immunosuppressive agent or agents has not been confirmed*.* [@bb0225] [@bb0230]

#### Diagnosis {#s0195}

The use of urine cytology to detect the presence of infected decoy cells in the urine has approximately 100% sensitivity for BK virus infection but a low (29%) predictive value.[@bb0230] [@bb0270] It is therefore a useful screening tool but cannot establish a firm diagnosis. The use of molecular techniques to screen blood or urine has also been advocated but is more useful in management of established cases (viral clearance with therapy) than in specific diagnosis.[@bb0275] Hirsch and colleagues[@bb0220] showed that patients with BK nephropathy have a plasma viral load statistically higher (\>7700 BK virus copies per ml of plasma, *p* \< 0.001) compared to patients without PVAN***.***

Given the presence of viremia in renal allograft recipients, it is critical to reduce immunosuppression. However, the possible coexistence of acute rejection with BK infection, present in 12% of cases, makes renal biopsy essential for the management of such patients. Drachenberg[@bb0255] [@bb0280] grades the histology of PVAN in three stages based on the degree of inflammation and fibrosis. In stage 1 cytopathic changes are present in the biopsy with minimal or no fibrosis. Stage 2 presents with cytopathic changes and, in addition, various degrees of inflammation and fibrosis. Stage 2 is subdivided into A, B, or C depending on the degree of inflammation/fibrosis: A less than 25%, B 25% to 50%, and C greater than 50%. Finally stage 3, with intensive fibrosis, is indistinguishable from any kind of end-stage kidney disease. Immunostaining for cross-reacting SV40 virus demonstrates patchy staining of viral particles within tubular cells in stages 1 and 2, but not in stage 3.

#### Treatment {#s0200}

The cornerstone treatment of PVAN continues to be reduction/adjustment in the intensity of immunosuppression. Ramos and colleagues[@bb0225] and Drachenberg and colleagues[@bb0215] have reported an algorithm used at the University of Maryland for early diagnosis and treatment of PVAN. Similarly, Ginevri and colleagues[@bb0205] have reported a similar successful protocol used in pediatric patients. It is possible to monitor the response to such interventions using urine cytology (decoy cells) and viral load measures in blood or urine, or both.[@bb0230] Regardless of the approach, renal function, drug levels, and viral loads must be monitored carefully.[@bb0270]

Additionally several agents with antipolyoma viral activity in vitro have been used to decrease in immunosuppression, including cidofovir in low doses (0.25-1 mg/kg every 2 weeks).[@bb0225] [@bb0230] Significant renal toxicity may be observed with this agent, especially in combination with the calcineurin inhibitors. Other agents include leflunomide, quinolones and intravenous immunoglobulins (IVIG).[@bb0285], [@bb0290], [@bb0295], [@bb0300] None of these agents are FDA approved for the treatment of PVAN. Additionally, it is difficult to assess the efficacy of these agents since the number of cases published is relatively small, and no prospective randomized control trials have been conducted. Frequently these agents have been used in combination with decreased immunosuppression, and at times together.[@bb0285]

Retransplantation has been consistently successful in patients with graft loss due to PVAN, although recurrence of the infection is known to occur. Careful monitoring is warranted in retransplanted patients, particularly if there is evidence of some level of active viral replication.[@bb0305] [@bb0310]

#### JC Virus and Progressive Multifocal Encephalopathy {#s0205}

Infection of the central nervous system by JC polyoma virus (JCV) has been observed uncommonly in renal allograft recipients as progressive multifocal encephalopathy (PML).[@bb0315] [@bb0320] This condition generally presents with focal neurological deficits or seizures and may progress to death following extensive demyelination.[@bb0250] [@bb0320], [@bb0325], [@bb0330] PML may be confused with calcineurin neurotoxicity, and both may respond to a reduction in calcineurin inhibitor levels.[@bb0320] PML occurs almost exclusively in immunocompromised patients. The first case was in 1958, in a patient with chronic lymphocytic leukemia and Hodgkin disease.[@bb0250] At present, most of the patients diagnosed with this condition have AIDS.[@bb0330], [@bb0335], [@bb0340] Fourteen cases have been described in patients following renal transplantation.[@bb0320] Cases have also been described in lung, heart, and liver transplantations.[@bb0345], [@bb0350], [@bb0355]

#### Clinical Presentation {#s0210}

The most common presentation in PML includes motor weakness, cognitive abnormalities, and speech and visual field deficits.[@bb0325] Cranial nerve accessory deficits have also been reported.[@bb0360] [@bb0365] Seizures have been reported as high as 40% in one study.[@bb0370] Among the 14 cases in renal transplantation, nine have died. In the remainder, immunosuppression was reduced or discontinued.[@bb0320]

#### Diagnosis {#s0215}

CT of the brain shows lesions in the cerebral white matter.[@bb0375] However, cerebral MRI is more sensitive in detecting PML lesions. Typically, they appear as areas of increased intensity in the white matter in T2-weighted MRI scans.[@bb0380] [@bb0385] The CSF in PML patients can be normal or may contain increased protein with a few cells, none of which are diagnostic of PML. JC virus DNA PCR in CSF may be obtained, but is not diagnostic and must be confirmed by brain biopsy.[@bb0390] [@bb0395] The latter reveals multiple asymmetrical foci of demyelination in the white matter with cytopathic astrocytes and characteristic JC particles in the nuclei of the oligodendrocytes.[@bb0400]

#### Differential Diagnosis {#s0220}

In renal transplantation patients with neurological abnormalities similar to the ones seen in patients with PML, the differential diagnosis could include cerebral toxoplasmosis, lymphoma, and calcineurin-induced neurotoxicity.[@bb0320] Characteristic CT and MRI features and cerebral biopsy with SV40 immunostaining help confirm the diagnosis.[@bb0375], [@bb0380], [@bb0385]

#### Treatment {#s0225}

Treatment with highly active antiretroviral therapy HAART in HIV patients has been beneficial in treating PML.[@bb0395] [@bb0405] [@bb0410] In patients with renal transplants, despite the known anti-JC polyoma effect in vitro of cidofovir,[@bb0415] [@bb0420] cytosine arabinoside,[@bb0425] [@bb0430] retinoic acid, and IFN-alpha, none of these compounds have been proven to be clinically effective. Koralnik and associates[@bb0435] have shown that JC virus-specific cytotoxic T lymphocytes may be promising in controlling JC viral replication and the progression of the disease. At the present time, modulation of immunosuppression is the only reliable method of treatment available.[@bb0320] Early diagnosis with aggressive treatment is of utmost importance in controlling this devastating disease.

Fungal Infections {#s0230}
-----------------

In addition to the endemic mycoses, transplant recipients are at risk for opportunistic infection with a variety of fungal agents, the most important of which are *Candida* species, *Aspergillus* species, and *C. neoformans*.

### *Candida* Species {#s0235}

*Candida* is the most common fungal pathogen, with *Candida albicans* and *Candida tropicalis* accounting for 90% of the infections. Mucocutaneous candidal infection (e.g., oral thrush, esophageal infection, cutaneous infection at intertriginous sites, vaginitis) occurs particularly when candidal overgrowth is promoted by the presence of high levels of glucose and glycogen in tissues and fluids (e.g., with poorly controlled diabetes, high-dose steroid therapy) and by broad-spectrum antibacterial therapy. These infections are usually treatable through correction of the underlying metabolic abnormality and topical therapy with clotrimazole or nystatin. More difficult to manage is candidal infection occurring in association with the presence of foreign bodies that violate the mucocutaneous surfaces of the body (e.g., vascular access catheters, surgical drains, and bladder catheters). Optimal management of these infections requires removal of the foreign body and systemic antifungal therapy with fluconazole, an echinocandin, or an amphotericin product.

A special problem in renal transplant recipients is candiduria, even if the patient is asymptomatic. Particularly in individuals with poor bladder function, obstructing fungal balls can develop at the ureteropelvic junction, resulting in obstructive uropathy, ascending pyelonephritis, and the possibility of systemic dissemination. A single positive culture result for *Candida* species from a blood specimen necessitates systemic antifungal therapy, because this finding carries a risk of visceral invasion of more than 50% in this population. Fluconazole (400-800 mg/day, with adjustment for renal dysfunction), because of its better safety profile, is usually used as initial therapy, unless the patient is critically ill or has a fluconazole-resistant species (e.g., *Candida glabrata* or *Candida krusei*). In these instances, therapy is with an echinocandin or amphotericin B, usually in a lipid preparation. Flucytosine may be useful as an adjunctive therapy in resistant infections but must be guided by drug levels and attention to hematopoietic toxicity.

### *Aspergillus* Species {#s0240}

Invasive aspergillosis is a medical emergency in the transplant recipient, with the portal of entry being the lungs and sinuses in more than 90% of patients and the skin in most of those remaining. Two species, *Aspergillus fumigatus* and *Aspergillus flavum*, account for most of these infections, although amphotericin-resistant isolates (*Aspergillus terreus*) are occasionally recognized. The pathological hallmark of invasive aspergillosis is blood vessel invasion, which accounts for the three clinical characteristics of this infection: tissue infarction, hemorrhage, and systemic dissemination with metastatic invasion. Early in the course of transplantation, central nervous system involvement with fungal infection is most often due to *Aspergillus* species, as was exemplified in a recent case report;[@bb0440] later after transplantation, other fungi (Zygomycetes, dematiaceous fungi) are increasingly prominent, with a high mortality rate.[@bb0445] The drug of choice for *Aspergillus* infection is probably voriconazole, noting the intense interactions between this agent and the calcineurin inhibitors and sirolimus. Liposomal amphotericin is a reasonable alternative, and combination therapies are under study. Of note, surgical debridement is often essential for the successful clearance of such invasive infections.

Central Nervous System Infection and *Cryptococcus neoformans* {#s0245}
--------------------------------------------------------------

Central nervous system (CNS) infection in the transplant recipient is an important differential for the clinician. The spectrum of causative organisms is broad and must be considered in terms of the timeline for infection in this population. Many infections are metastatic to the CNS, often from the lungs. Thus, a "metastatic workup" is a component of evaluation of CNS lesions, including those due to *Aspergillus, Cryptococcus, Nocardia,* or *S. stercoralis*. Viral infections include cytomegalovirus (nodular angiitis), herpes simplex meningoencephalitis, JCV, PML, and varicella zoster virus. Common bacterial infections include *L. monocytogenes*, mycobacteria, and *Nocardia*. Brain abscess and epidural abscess may be observed with MRSA, while penicillin-resistant pneumococcus and quinolone-resistant streptococci can be problematic. Metastatic fungi include *Aspergillus* and *Cryptococcus* but also spread from sinuses (Mucoraceae), skin (Dematiaceae), and bloodstream (*Histoplasma* and *Pseudallescheria/Scedosporium*, *Fusarium* species). Parasites include *T. gondii. T. cruzi,* and *Strongyloides*. Given the spectrum of etiologies, precise diagnosis is essential. In the proper settings, empiric therapy should "cover" *Listeria* (ampicillin), *Cryptococcus* (fluconazole or amphotericin), and HSV (acyclovir) while awaiting data from lumbar puncture, blood cultures, and radiographic studies. Included in the differential diagnosis are noninfectious etiologies, including calcineurin inhibitor toxicity, aseptic meningitis from trimethoprim/sulfamethoxazole (TMP-SMX), lymphoma, and metastatic cancer. Biopsy may be needed for a firm diagnosis.

### Cryptococcus neoformans {#s0250}

The most common presentation of cryptococcal infection is that of an asymptomatic pulmonary nodule, often with active organisms present. In the "chronic ne'er-do-well" patient, pneumonia and meningitis are common with skin involvement at sites of tissue injury (catheters) also being observed. Cryptococcosis should be suspected in transplant recipients present with unexplained headaches (especially when accompanied by fevers), decreased state of consciousness, failure to thrive, or unexplained focal skin disease (which requires biopsy for culture and pathological evaluation) more than 6 months after transplantation. Diagnosis is often achieved by serum cryptococcal antigen detection, but all such patients should have lumbar puncture for cell counts and cryptococcal antigen studies. Initial treatment is probably best with amphotericin and 5-flucytosine followed by high dose fluconazole until the cryptococcal antigen is cleared from blood and CSF. Scarring and hydrocephalus may be observed.

Pneumonia and Pneumonitis {#s0255}
-------------------------

The spectrum of potential pathogens of the lungs in transplantation is too broad for this discussion. As for all infections in transplantation, invasive diagnostic techniques are often necessary in these hosts. The depressed inflammatory response of the immunocompromised transplant patient may greatly modify or delay the appearance of a pulmonary lesion on radiograph. Focal or multifocal consolidation of acute onset will quite likely be caused by bacterial infection. Similar multifocal lesions with subacute to chronic progression are more likely secondary to fungi, TB, or nocardial infections. Large nodules are usually a sign of fungal or nocardial infection, particularly if they are subacute to chronic in onset. Subacute disease with diffuse abnormalities, either of the peribronchovascular type or miliary micronodules, are usually caused by viruses (especially CMV) or *P. jiroveci*.[@bb0335] [@bb0340] Additional clues can be found by examining pulmonary lesions for cavitation; cavitation suggests such necrotizing infections as those caused by fungi (*Aspergillus* or *Mucoraceae*), *Nocardia, Staphylococcus,* and certain gram-negative bacilli, most commonly with *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*.[@bb0345] CT of the chest is useful when the chest radiograph is negative or when the radiographic findings are subtle or nonspecific. CT also is essential to the definition of the extent of the disease process and the possibility of multiple simultaneous processes (superinfection) and to guide the selection of the optimal invasive technique to achieve microbiological diagnosis.

### *Pneumocystis jiroveci* Pneumonia {#s0260}

The risk of infection with *Pneumocystis* is greatest in the first 6 months after transplantation and during periods of increased immune suppression.[@bb0025] [@bb0335] [@bb0340] The natural reservoir of infection remains unknown. Aerosol transmission of infection has been demonstrated by a number of investigators in animal models, and clusters of infections have developed in clinical settings, including between HIV-infected persons and renal transplant recipients. Activation of latent infection remains a significant factor in the incidence of disease in immunocompromised hosts. In the solid organ transplant recipient, chronic immune suppression that includes corticosteroids is most often associated with pneumocystosis. Bolus corticosteroids, cyclosporine, or coinfection with CMV may also contribute to the risk for PCP.

In patients not receiving TMP-SMX (or alternative drugs) as prophylaxis, most transplant centers report an incidence of *P. jiroveci* pneumonia of approximately 10% in the first 6 months posttransplantation. There is a continued risk of infection in three overlapping groups of transplant recipients as follows: 1) those who require higher than normal levels of immune suppression for prolonged periods of time due to poor allograft function or chronic rejection, 2) those with chronic CMV infection, and 3) those undergoing treatments that increase the level of immune deficiency, such as cancer chemotherapy or neutropenia due to drug toxicity. The expected mortality due to *Pneumocystis* pneumonia is increased in patients on cyclosporine when compared to other immunocompromised hosts. The hallmark of infection due to *P. jiroveci* is the presence of marked hypoxemia, dyspnea, and cough with a paucity of physical or radiological findings. In the transplant recipient, *Pneumocystis* pneumonia is generally acute to subacute in development. Atypical *Pneumocystis* infection (radiographically or clinically) may be seen in patients who have coexisting pulmonary infections or who develop disease while receiving prophylaxis with second choice agents (e.g., pentamidine or atovaquone).[@bb0450] Patients outside the usual period of greatest risk for PCP may present with indolent disease confused with heart failure. In such patients, diagnosis often has to be made by invasive procedures. A number of patients have been identified with interstitial pneumonitis while receiving sirolimus, especially in the setting of reduced creatinine clearance;[@bb0455] the clinical presentation may mimic PCP.

#### Diagnosis {#s0265}

The characteristic hypoxemia of *Pneumocystis* pneumonia produces a broad alveolar-arterial P[o]{.smallcaps} ~2~ gradient. The level of serum lactic dehydrogenase (LDH) is elevated in most patients with *Pneumocystis* pneumonia (\>300 international units/ml). However, many other diffuse pulmonary processes also raise serum LDH levels. The fungal marker, 1,3-beta-D-glucan, may be markedly positive with PCP.[@bb0460]

Like many of the "atypical" pneumonias (pulmonary infection without sputum production), no diagnostic pattern exists for *Pneumocystis* pneumonia on routine chest radiograph. The chest radiograph may be entirely normal or develop the classical pattern of perihilar and interstitial "ground glass" infiltrates. Microabscesses, nodules, small effusions, lymphadenopathy, asymmetry, and linear bands are common. Chest CT scans will be more sensitive to the diffuse interstitial and nodular pattern than routine radiographs. The clinical and radiographic manifestations of *P. jiroveci* pneumonia are virtually identical to those of CMV. Indeed, the clinical challenge is to determine whether both pathogens are present. Significant extrapulmonary disease is uncommon in the transplant recipient.

Identification of *P. jiroveci* as a specific etiological agent of pneumonia in an immunocompromised patient should lead to successful treatment. A distinction should be made between the diagnosis of *Pneumocystis* infection in AIDS and in non-AIDS patients. The burden of organisms in infected AIDS patients is generally greater than that of other immunocompromised hosts and noninvasive diagnosis (sputum induction) more often achieved. In general, noninvasive testing should be attempted to make the initial diagnosis, but invasive techniques should be used when clinically feasible. The diagnosis of *P. jiroveci* infection has been improved by the use of induced sputum samples and of immunofluorescent monoclonal antibodies to detect the organism in clinical specimens. These antibodies bind both cysts and trophozoites. The cyst wall can be displayed by a variety of staining techniques; of these, the Gomori methenamine-silver nitrate method (which stains organisms brown or black) is most reliable, even though it is susceptible to artifacts. Sporozoites and trophozoites are stained by polychrome stains, particularly the Giemsa stain.

#### Therapy {#s0270}

Early therapy, preferably with TMP-SMX, is preferred. In renal transplant recipients, there may be an elevation of creatinine due to trimethoprim (competing for secretion in the kidney) and the toxicity of sulfa agents for the renal allograft. Hydration and the gradual initiation of therapy may help. Alternate therapies are less desirable but have been used with success, including intravenous pentamidine, atovaquone, clindamycin with primaquine or pyrimethamine, and trimetrexate. Although a reduction in the intensity of immune suppression is generally considered a part of antiinfective therapy in transplantation, the use of short courses of adjunctive steroids with a gradual taper is sometimes used in transplant recipients (as in AIDS patients) with severe respiratory distress associated with PCP.

The importance of preventing *Pneumocystis* infection cannot be overemphasized. Low dose TMP-SMX is the most effective agent for prevention, is well-tolerated, and should be used in the absence of concrete data demonstrating true allergy. Alternative prophylactic strategies, including atovaquone, dapsone, inhaled or intravenous pentamidine, are less effective than TMP-SMX but useful in the patient with significant allergy to sulfa drugs. The advantages of TMP-SMX include increased efficacy, lower cost, the availability of oral preparations, and possible protection against other organisms, including *T. gondii, Isospora belli, Cyclospora cayetanensis, N. asteroides*, and common urinary, respiratory, and gastrointestinal bacterial pathogens. It should be noted that alternative agents lack this spectrum of activity.

Vaccination {#s0275}
-----------

Because of concerns about the efficacy of vaccines following transplantation, patients should complete vaccinations at least 1 month before to allow time for an optimal immune response. Pretransplant serologies should include varicella, measles, mumps, and rubella; vaccination for these should be performed at least 1 month, and preferably 3 months, before transplantation for resolution of viremia from live vaccines, and only in patients not actively on immunosuppression. Vaccinations should include routine adult vaccines, including pneumococcal vaccine (if not vaccinated in the last 3-5 years), tetanus booster, hepatitis A, hepatitis B, and varicella zoster (Zostavax) ([Table 38-7](#t0040){ref-type="table"} ).[@bb0465] After transplantation, influenza vaccination should be performed yearly or as per local guidelines. Live vaccines such as nasal influenza, varicella and varicella zoster, measles, mumps, rubella, yellow fever, smallpox, and oral typhoid are not usually given after solid organ transplantation because of safety concerns. Travel-related vaccines and medical advice should be considered both before and after transplantation.[@bb0470] Annually updated recommended schedules and doses for routine vaccinations can be obtained from the United States Centers for Disease Control and Prevention (CDC) at [www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm](http://www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm){#ir0010} or the CDC Immunization Information Hotline, (800) 232-4636.TABLE 38-7Vaccinations to Consider Prior to TransplantationMMRTdapHepatitis BHepatitis AHPVPneumococcusInfluenzaVaricella and varicella zoster[^9]
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[^1]: *HIV*, human immuodeficiency virus; *HTLV*, human T lymphotroic virus; *LCMV*, lymphocytic choriomeningitis virus; *MRSA*, methicillin-resistant staphylococci; *RSV*, respiratory syncytial virus; *VRE*, vancomycin-resistant enterococci.

[^2]: *CMV*, cytomegalovirus; *EBV*, Epstein-Barr virus; *HIV*, human immunodeficiency virus; *RSV*, respiratory syncytial virus.

[^3]: *CMV*, cytomegalovirus; *EBV*, Epstein-Barr virus; *HBV*: HbsAg, hepatitis B surface antigen; *HCV*, hepatitis C virus; *HIV*, human immunodeficiency virus; *HSV*, herpes simplex virus; *PPD*, purified protein derivative (tuberculin); *VZV*, varicella zoster virus.

[^4]: *CJD*, Creutzfeldt-Jacob disease; *EBV*, Epstein-Barr virus; *HIV*, human immunodeficiency virus; *HTLV*, human T lymphotroic virus; *SARS*, severe acute respiratory syndrome.

[^5]: Must be considered in the context of the individual donor and recipient.

[^6]: *CMV*, cytomegalovirus; *MMF*, mycophenolate mofetil; *PCP*, *Pneumocystis jiroveci* pneumonia.

[^7]: *ACV*, acyclovir; *CMV*, cytomegalovirus; *EBV*; Epstein-Barr virus; *GFR*, glomerular filtration rate; *HHV*, human herpes virus; *HSV*, herpes simplex viruses; *PCP*, *Pneumocystis jiroveci* pneumonia; *TMP-SMX*, trimethoprim-sulfamethoxazole; *VZV*, varicella-zoster virus.

[^8]: Note: Not approved by the U.S. Food and Drug Administration at these doses.

[^9]: *MMR,* measles/mumps/rubella; *Tdap,* diphtheria/tetanus/pertussi; *HPV,* human papilloma virus.
